Therapeutic drug monitoring in inflammatory bowel disease

RDF 

 
This item is provided by the institution :
Hellenic Gastroenterologiki Company
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
Therapeutic drug monitoring in inflammatory bowel disease (EN)

Kopylov, Uri; McGill University Health Center Montreal
Seidman, Ernest; Professor of Medicine & Pediatrics Canada Research Chair in Immune Mediated Gastrointestinal Disorders Bruce Kaufman Endowed Chair in IBD at McGill Digestivelab, Research Institute of McGill Univercity Health Center, MGH Campus Montreal
Ben-Horin, Shomron; Sheba Medical Center Tel Hashomer, Ramat Gan

none (EN)

Tumor necrosis factor (TNF)-α inhibitors and thiopurines are among the most important classes of medications utilized in the clinical management of Crohn’s disease and ulcerative colitis. A significant proportion of patients loses response to these agents or develops adverse effects during the course of the treatment. Monitoring of drug levels and anti-drug antibodies (for TNF-α inhibitors) and metabolite levels (for thiopurines) can provide valuable insight into the possible etiology of unfavorable outcomes and allow for an appropriate management strategy for these patients. This review summarizes the current knowledge on the clinical implications of therapeutic drug monitoring in inflammatory bowel disease patients treated with TNF-α inhibitors and thiopurines.Keywords Inflammatory bowel disease, Crohn’s disease, ulcerative colitis, biologics, thiopurinesAnn Gastroenterol 2014; 27 (4): 304-312 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2014-10-02


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 27, No 4 (2014); 304 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)